- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04570631
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to determine recommended Phase 2 dose and change in disease symptoms of eftozanermin alfa in combination with bortezomib and dexamethasone to assess how efficient the treatment is in adult participants with relapsed/refractory (R/R) MM.
Eftozanermin alfa (ABBV-621) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). Study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. Participants in one arm will receive different doses of eftozanermin alfa in combination with bortezomib and dexamethasone to determine phase 2 dose (RP2D). Participants in the other arm will receive eftozanermin alfa at RP2D in combination with bortezomib and dexamethasone. Around 40 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 20 sites across the world.
Participants will receive eftozanermin alfa as an infusion into the vein in combination with bortezomib as an infusion into the vein or an injection under the skin and oral dexamethasone tablets for 12 cycles. Each cycle is 21 days for cycles 1-8 and 35 days for cycles 9-12.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Auvergne-Rhone-Alpes
-
Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France, 69495
- HCL - Hopital Lyon Sud /ID# 222304
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, France, 13009
- Institut Paoli-Calmettes /ID# 222307
-
-
Hauts-de-France
-
Lille, Hauts-de-France, France, 59037
- CHRU Lille - Hopital Claude Huriez /ID# 222302
-
-
Pays-de-la-Loire
-
Nantes, Pays-de-la-Loire, France, 44000
- CHU de Nantes, Hotel Dieu -HME /ID# 222303
-
-
Val-de-Marne
-
Villejuif Cedex, Val-de-Marne, France, 94805
- Institut Gustave Roussy /ID# 223951
-
-
-
-
-
Berlin, Germany, 12203
- Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 223014
-
Hamburg, Germany, 20246
- Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 222258
-
Mainz, Germany, 55131
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 222372
-
-
Nordrhein-Westfalen
-
Muenster, Nordrhein-Westfalen, Germany, 48149
- Universitaetsklinikum Muenster /ID# 222504
-
-
-
-
-
Meldola, Italy, 47014
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS /ID# 223839
-
-
Lazio
-
Rome, Lazio, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 223224
-
-
-
-
Aichi
-
Nagoya shi, Aichi, Japan, 467-8602
- Nagoya City University Hospital /ID# 222408
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- National Cancer Center Hospital East /ID# 239436
-
-
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
- Hospital Duran i Reynals /ID# 222329
-
-
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University, Winship Cancer Institute /ID# 222922
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Center /ID# 222918
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute /ID# 222174
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Hospital /ID# 222166
-
-
Texas
-
Dallas, Texas, United States, 75390-7208
- University of Texas Southwestern Medical Center /ID# 223811
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria.
Has measurable disease at screening, defined by at least 1 of the following:
- Serum M-protein >= 1.0 g/dL (>= 10 g/L); OR
- Urine M-protein >= 200 mg/24 hours; OR
- Serum free light chain (sFLC) >= 10 mg/dL (100 mg/L), provided serum FLC ratio is abnormal.
- Relapsed or refractory MM after receiving at least 3, but no more than 6 prior lines of therapy, including an immunomodulatory agent (IMiD), proteasome inhibitor (PI), and an anti-CD38 antibody, and has documented disease progression that occurred during or after the most recent therapy.
- Has adequate hematologic, hepatic and renal function as defined in the protocol.
- Eastern Cooperative Oncology Group (ECOG) 0 or 1.
- Life expectancy >= 12 weeks.
Exclusion Criteria:
- Received bortezomib as part of the most recent prior therapy.
- Has primary refractory disease defined as disease that is non-responsive.
- Has not achieved a minimal response or better per IMWG criteria with any therapy.
- Has discontinued bortezomib due to toxicity.
- History of chronic liver disease or significant unresolved liver disease; currently active (within the last 6 months) hepatic impairment according to Child-Pugh Classification B or C.
- History of cataract surgery within 6 months prior to study treatment and participant is not anticipated to have cataract surgery during the study treatment period (as assessed by ophthalmological exam at baseline).
- Evidence of (as assessed by ophthalmological exam at baseline) uveitis, neovascular age related macular degeneration, retinal vein or artery occlusion and/or macular edema; no evidence of moderate or worsening diabetic retinopathy, retinal vascular disease or glaucoma (including participants with history of developing increased intraocular pressure after corticosteroid treatment) per clinical discretion of the consulting eye specialist.
- Peripheral neuropathy Grade >= 2 or Grade 1 with pain.
Receipt of one of the following:
- Corticosteroids at a dose equivalent to > 4 mg daily of dexamethasone or a single dose of > 40 mg of dexamethasone within 2 weeks prior to first dose.
- Monoclonal antibodies used for multiple myeloma treatment within 4 weeks prior to first dose of study treatment.
- Any other systemic therapies used for multiple myeloma treatment within 5 half-lives or 2 weeks prior to first dose, whichever is longer (or 2 weeks if half-life is unknown).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Safety Lead-in
Participants will receive escalating doses of eftozanermin alfa in combination with bortezomib and dexamethasone to determine recommended phase 2 dose (RP2D).
|
Intravenous (IV) infusion
Other Names:
Intravenous (IV) or Subcutaneous (SC) injection
Oral Tablet
|
Experimental: Dose Expansion
Participants will receive eftozanermin alfa at RP2D determined in Safety Lead-in part in combination with bortezomib and dexamethasone.
|
Intravenous (IV) infusion
Other Names:
Intravenous (IV) or Subcutaneous (SC) injection
Oral Tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Phase 2 Dose (RP2D) of Eftozanermin Alfa in Combination With Bortezomib and Dexamethasone (Safety Lead-In Arm)
Time Frame: Up to approximately 3 weeks after the first dose of study drug
|
RP2D of eftozanermin alfa in combination with bortezomib and dexamethasone will be determined.
|
Up to approximately 3 weeks after the first dose of study drug
|
Objective Response Rate (ORR) (Dose Expansion Arm)
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
ORR is defined as percentage of participants with a response of partial response (PR) or better per International Myeloma Working Group (IMWG) criteria.
|
Up to approximately 44 weeks after the first dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR) for ORR
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
DOR for ORR is defined as the number of days from the date of first response (PR or better) to the date of first occurrence of progressive disease (PD) or death from any cause, whichever occurs first.
|
Up to approximately 44 weeks after the first dose of study drug
|
Duration of Response (DOR) for VGPR or Better
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
DOR for VGPR or better rate is defined as the number of days from the date of first response (VGPR or better) to the date of first occurrence of PD or death from any cause, whichever occurs first.
|
Up to approximately 44 weeks after the first dose of study drug
|
Number of Participants With Dose-Limiting Toxicities (DLTs)
Time Frame: Up to approximately 3 weeks after the first dose of study drug
|
DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of study drug as described in the protocol and evaluated by the Investigator and the sponsor.
|
Up to approximately 3 weeks after the first dose of study drug
|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
The investigator will assess the relationship of each event to the use of study drug as being of reasonable possibility or no reasonable possibility.
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
|
Up to approximately 44 weeks after the first dose of study drug
|
Change in Vital Sign Measurements
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
Change from baseline in vital sign measurements such as systolic and diastolic blood pressure will be assessed.
|
Up to approximately 44 weeks after the first dose of study drug
|
Electrocardiogram (ECG)
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
Participants with change from baseline in ECG variables will be assessed.
|
Up to approximately 44 weeks after the first dose of study drug
|
Number of Participants With Abnormal Clinical Laboratory Test Results
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
Number of participants with abnormal clinical laboratory test results like hematology will be assessed.
|
Up to approximately 44 weeks after the first dose of study drug
|
Trough Concentration (Ctrough) of Eftozanermin Alfa
Time Frame: Up to Day 106
|
Serum concentration prior to administration of study drug.
|
Up to Day 106
|
Maximum Serum Concentration (Cmax) of Eftozanermin Alfa
Time Frame: Up to Day 8
|
Serum concentration at 15 min after end of infusion.
|
Up to Day 8
|
Antidrug Antibody (ADA)/Neutralizing Antibody (Nab) Assay
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
Serum sample assay for ADA/Nab (Nabs will be analyzed only upon request).
|
Up to approximately 44 weeks after the first dose of study drug
|
Rate of Very Good Partial Response (VGPR) or Better per IMWG Criteria
Time Frame: Up to approximately 44 weeks after the first dose of study drug
|
Percentage of participants with a response of VGPR or better per IMWG criteria will be assessed.
|
Up to approximately 44 weeks after the first dose of study drug
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
- Bortezomib
Other Study ID Numbers
- M20-258
- 2020-001983-26 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Eftozanermin alfa
-
ShireCompleted
-
Jonsson Comprehensive Cancer CenterAmgenCompletedLymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant ConditionUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Clinical Affairs, L.L.C.TerminatedNeoplasms | Cancer | AnemiaUnited States
-
Philogen S.p.A.RecruitingCarcinoma, Basal Cell | Carcinoma, Cutaneous Squamous CellGermany, Poland, Switzerland
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsTaiwan, United Kingdom, Thailand, Serbia, Croatia, Italy, Poland, Romania, Hungary, Malaysia, United States, Austria, Brazil, Greece, Japan, Puerto Rico, Russian Federation, South Africa, Turkey
-
University of California, San FranciscoDuke UniversityRecruitingWolman Disease | MPS IVA | Pompe Disease Infantile-Onset | Gaucher Disease, Type 2 | MPS VI | MPS I | Gaucher Disease, Type 3 | MPS II | Mps VIIUnited States
-
Philogen S.p.A.RecruitingKaposi Sarcoma | Merkel Cell Carcinoma | BCC - Basal Cell Carcinoma | SCC - Squamous Cell Carcinoma | Keratoacanthoma of Skin | Malignant Adnexal Tumors of the Skin (MATS) | Tumors From Cutaneous T-cell Lymphoma (CTCL)Spain, France, Italy
-
Hoffmann-La RocheTerminatedIdiopathic Pulmonary FibrosisKorea, Republic of, United States, France, Israel, Spain, Belgium, Australia, Czechia, Denmark, Taiwan, Italy, Japan, Singapore, Turkey, Germany, China, New Zealand, Argentina, Portugal, South Africa, Hungary, Canada, Poland, Greece, Ne... and more
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BUnited States, Spain, Taiwan, Turkey, Poland, Croatia, Italy, Malaysia, Brazil, United Kingdom, Hungary, Israel, Thailand, Japan, South Africa, Canada, France, Argentina